Cat allergy immunotherapy(Circassia Group Plc)

This article immunol. changes in peripheral blood samples obtained from individuals with allergic rhinitis (AR), triggered by exposure to cat allergen, who were receiving peptide immunotherapy.Ten cat-sensitized AR individuals received cat-peptide antigen desensitization peptide immunotherapy for AR; participants were treated with four intradermal injections (at 4-wk intervals) of 6 nmol Cat-PAD.In analyses of complete blood count (CBC) data, frequencies of immune cells neutrophils, lymphocytes, and monocytes at V3 were significantly different from at V1A.Lower expression of immune genes at V3 was associated with IL-2-, IL-4-, IL-6-, granulocyte-macrophage colony-stimulating factor and B-cell receptor signaling pathway-mediated signaling events; conversely, higher expression of immune genes at V3 was associated with T-cell receptor signaling in CD4+ and CD8+ T cells and IL-12-mediated signaling events.Five immune genes with significant gene expression patterns were identified: integrin subunit alpha E (ITGAE, CD103), CD180 (LY64), (NCAM1, CD56), C-C motif chemokine receptor 7 (CCR7, CD197), And leucine-rich repeat neuronal 3 (LRRN3).Cellular and genetic approaches in peripheral blood with NAC may identify predictors of treatment efficacy and better pheno- or endo-typing for precision medicine.